Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in Japan Jan. 18, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &amp, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) approved VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) injectio ...

One stock that might be an intriguing choice for investors right now is argenx SE (ARGX) . This is because this security in the Medical - Biomedical and Genetics space is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the ...

Reported $1.2 billion in preliminary* full-year 2023 global net product sales Submitted sBLA to FDA for VYVGART® Hytrulo for CIDP with priority review voucher (PRV); if approved, launch expected mid-2024 Reported positive data from Phase 2 ARDA study establishing proof-of-concept for empasiprubart in MMN Data from six Phase 2 proof-of-concept trials expected by end of 2024 Nominated four new pipeline candidates with IND filings expected by end of 2025 January 8, 2024, 7:00 AM CET Amsterdam, the Netherlands ...

argenx SE (NASDAQ:ARGX) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications and IR Tim Van Hauwermeiren - CEO Karl Gubitz - CFO Karen Massey - COO Conference Call Participants Yatin Suneja - Guggenheim Partners Tazeen Ahmad - Bank of America Derek Archila - Wells Fargo Thomas Smith - Leerink Partners James Gordon - JPMorgan Amy Li - Jefferies Danielle Brill - Raymond James Yaron Werber - TD Cowen Myles Minter - Willi ...

argenx SE (NASDAQ:ARGX) Q2 2023 Earnings Conference Call July 27, 2023 8:30 AM ET Company Participants Beth DelGiacco - VP and Global Head, Corporate Communications & IR Tim Van Hauwermeiren - CEO & Executive Director Karl Gubitz - CFO Karen Massey - COO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Derek Archila - Wells Fargo Securities Yaron Werber - TD Cowen Danielle Brill - Raymond James & Associates Amy Li - Jefferies Xian Deng - UBS Joon Lee - Truist Securities Samantha Sem ...

Half Year 2023 Financial Results and Second Quarter Business Update Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain a ...

Exhibit 99.1 argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China ● First-and-only approved FcRn antagonist for gMG patients by NMPA ● 68% of anti-AChR antibody positive gMG patients treated with VYVGART were responders (n=44/65) on the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale compared with 30% of patients treated with placebo (n=19/64) (p<0.0001) during the first treatment cycle in the Phase 3 ADAPT trial ● Zai Lab to s ...

argenx SE (NASDAQ:ARGX) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Beth DelGiacco - Vice President of Corporate Communications and Investor Relations Tim Van Hauwermeiren - Chief Executive Officer Karl Gubitz - Chief Financial Officer Karen Massey - Chief Operating Officer Conference Call Participants Derek Archila - Wells Fargo Tazeen Ahmad - Bank of America Rajan Sharma - Goldman Sachs Yatin Suneja - Guggenheim Akash Tewari - Jefferies Thomas Smith - SVB Security Danielle ...

First Quarter 2023 Financial Results and Business Update May 4, 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain ...

argenx • Together We Discover Corporate Presentation April 2023 Forward Looking Statements This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presentation does not purport to be all-inclusive or to contain all o ...